You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
花旗:首予亞盛醫藥(6855.HK)“買入”評級 目標價50港元
格隆匯 12-06 09:55
格隆匯12月6日丨花旗發表報告指,亞盛醫藥(6855.HK)旗下治療慢性髓性白血病的產品HQP1351正處於關鍵II期臨牀試驗階段,目標在2020年提交新藥上市申請,預計申請有望於2021年獲批,最高銷售收入將可達25億元人民幣,首予“買入”評級。 
報告指出,臨牀實驗結果顯示HQP1351具有良好的耐受性,與同類型產品第三代BCR-ABL抑制劑帕那替尼相比安全性更好。加上考慮到亞盛於上市時引入中生製藥(1177.HK)為基石投資者,期望雙方或進行潛在合作,例如亞盛可利用中生製藥強大的中國銷售團隊及醫院覆蓋率,中生製藥也可藉此充實抗腫瘤產品。 
花旗以亞盛候選產品的相當於4倍峯值銷售(經風險調整後)的產品折現估值分部加總,並以貼現現金流法估值(DCF)作為參考, 給予目標價50港元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account